OnKure Therapeutics Pre-Tax Income 2020-2024 | OKUR

OnKure Therapeutics pre-tax income from 2020 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.

OnKure Therapeutics Pre-Tax Income 2020-2024 | OKUR

OnKure Therapeutics pre-tax income from 2020 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.1B
Takeda Pharmaceutical (TAK)$44.8B
Merck (MKGAF)$21.8B
Astellas Pharma (ALPMY)$20.6B
Sandoz Group AG (SDZNY)$18.4B
Summit Therapeutics (SMMT)$17B
United Therapeutics (UTHR)$16.5B
Shionogi (SGIOY)$12.2B
Neurocrine Biosciences (NBIX)$12B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Jazz Pharmaceuticals (JAZZ)$7.1B
Ionis Pharmaceuticals (IONS)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.9B
Crinetics Pharmaceuticals (CRNX)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.7B
Dyne Therapeutics (DYN)$3.6B
PTC Therapeutics (PTCT)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$2B
Harrow (HROW)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Ocular Therapeutix (OCUL)$1.8B
NewAmsterdam Pharma (NAMS)$1.7B
ARS Pharmaceuticals (SPRY)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B